Method of controlling emesis caused by cisplatin in cancer chemotherapy
AssigneeA. H. Robins Company, Incorporated
InventorRobert E. Keenan
Life of this patent
Estimating the term…
Abstract
High dosages of metoclopramide or a pharmaceutical salt thereof is administered intravenously to human cancer patients undergoing cisplatin chemotherapy to prevent emesis.
Claims7
A method for alleviating emesis in human cancer patients caused by cisplatin chemotherapy which comprises administering about 5 to 18 mg of metoclopramide or a pharmaceutically acceptable salt thereof per kg of patient body weight over a period of time spanning about 30 minutes prior to cisplatin administration through the post administration period, said metoclopramide or the pharmaceutically acceptable salt thereof being administered either continuously or as 4 to 7 individually spaced dosages about 11/2 to 3 hours apart.
Dependencies are inferred from the claim text.